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Influenza Virus Infection of the Murine Uterus: A New Model
for Antiviral Immunity in the Female Reproductive Tract
KATHRYN B. RENEGAR,1–4 ALAN MENGE,5 and JIRI MESTECKY1
ABSTRACT
Secretory IgA (S-IgA) mediates local immunity to influenza virus in the murine upper respiratory
tract and may play an important role in local immunity to various microorganisms in the female
reproductive tract as well. Although the presence of IgA in cervicovaginal or uterine secretions has
been correlated with immunity to a number of pathogens, there has been no direct demonstration
of the mediation of uterine antiviral immunity by S-IgA. Influenza virus, although not a normal
pathogen of the reproductive tract, was used to develop a model for the investigation of mucosal
immunity in the uterus. PR8 (H1N1) influenza virus injected into the ovarian bursa of BALB/c mice
grew well, with peak titers between days 3 and 5. Intravenous injection of polymeric IgA anti-in-
fluenza virus monoclonal antibody before or 30 min after viral challenge protected mice against vi-
ral infection. We believe this work to be the first direct demonstration of S-IgA-mediated antiviral
uterine immunity. It provides a model for further investigation of immunity in the female repro-
ductive tract.
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INTRODUCTION
SECRETORY IgA (S-IgA), the major immunoglobulinisotype present at mucosal surfaces, is an important
factor in local immunity (20,35). S-IgA is derived from
the J chain-containing polymeric IgA (pIgA) produced
by plasma cells, which are found in large numbers in se-
cretory glands and in the lamina propria of mucosal tis-
sues (11,20). Polymeric IgA, present in the interstitial
fluid bathing the basolateral surfaces of the mucosal ep-
ithelial cells, is transported through these cells by the
transmembrane polymeric immunoglobulin receptor
(pIgR), which binds to the pIgA molecule and carries it
from the basolateral to the apical cell surface (12). There
the receptor is cleaved, releasing the S-IgA molecule con-
taining a large portion of the bound pIgR, known as se-
cretory component (SC), into the mucosal secretions
(4,20).
The majority of IgA-positive plasma cells in mucosal tis-
sues migrate there from IgA-inductive sites such as the gut-
associated lymphoid tissue (GALT) and the bronchus-as-
sociated lymphoid tissue (BALT) (20). Stimulation of these
IgA-inductive sites by antigens results in dissemination of
specific IgA-producing cells to effector sites throughout the
mucosal tissues (9,19,25,44), leading to the concept of a
common mucosal immune system (20).
The female reproductive tract is an integral part of this
common mucosal system (5,6,19). Immunization of the
respiratory tract with liposomes supplemented with in-
fluenza viral hemagglutinin, for example, stimulates an
IgA response in the murine uterus (9,44). There are nu-
merous studies correlating S-IgA production in the fe-
male reproductive tract with immunity (1,4,7,10,14–17,
21–23,25,27,36,43); however, a role for S-IgA in pro-
tection of the female reproductive tract against viral in-
fection has not been directly demonstrated.
In mice, plasma-derived pIgA can protect the upper
respiratory tract from viral infection, as the passive trans-
fer of nasal immunity to influenza virus has been ac-
complished via the intravenous injection of pIgA anti-in-
fluenza virus monoclonal antibody (mAb) (29,30,32,33).
Influenza virus replicates in fetal urogenital tissue from
ferrets (40), guinea pigs (39), and humans (34), as well
as in organ cultures of human and simian urogenital tis-
sues and in human endometrial cell lines (2,34). In the
work described in this paper, we investigated in a murine
model whether the uterus might support the growth of in-
fluenza virus and whether uterine immunity might then




Four- to 6-week-old female BALB/c mice for experi-
mental protocols or retired breeder female mice for as-
cites production were obtained from Charles River
Breeding Laboratories (Wilmington, MA) and main-
tained in an Association for the Assessment and Ac-
creditation of Laboratory Animal Care-accredited animal
facility. Food and water were supplied ad libitum. Ex-
perimental protocols were approved by an institutional
animal care and use committee.
Monoclonal IgA
Hybridoma H37-66-1, producing monoclonal pIgA
specific for the Sb epitope of the hemagglutinin of PR8
(A/PR8/34) H1N1 influenza virus, was the generous gift
of W. Gerhard (Wistar Institute, Philadelphia, PA) and
was generated as previously described (37). Hybridoma
Z-F11-15, producing a pIgA not reacting with influenza
virus, was the gift of Z. Moldoveanu (University of Al-
abama at Birmingham, Birmingham, AL). The hybrido-
mas were propagated as ascitic tumors in retired breeder
mice. Ascitic fluid was harvested, pooled, and stored at
70°C. Pooled H37-66-1 ascitic fluid contained pIgA at
8.6 mg/mL as determined by radial immunodiffusion as-
say (ICN ImmunoBiologicals, Lisle, IL); pooled Z-F11-
15 contained 5.7 mg/mL pIgA mAb. On the basis of the
amount of background IgA present in several IgG ascites
pools (radial immunodiffusion assay determination),
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H37-66-1 pools contained less than 3% nonspecific IgA
antibody. Both sucrose gradient sedimentation (30) and
ACA column chromatography (31) showed H37-66-1
pools to be composed of greater than 75% polymeric an-
tibody forms. Sedimentation analysis of H-37-66-1 pIgA
mAb collected from the nasotracheal lavages and bile of
intravenously injected mice showed that the mAb re-
tained its polymeric form on transport (30). Furthermore,
H-37-66-1 injected intravenously into a Lewis rat and
collected by bile duct cannulation acquired secretory
component as it was removed from the circulation (31),
indicating that it was a J chain-containing polymeric IgA
and not simply an aggregate of monomeric IgA mole-
cules.
Virus
A/PR8-Mt. Sinai (H1N1) influenza virus was the gift
of W. Gerhard. To generate a pool, virus was grown in
eggs, pooled, filtered through a 0.45-m pore size filter,
aliquoted, and stored at 70°C. Viral growth was as-
sayed in Madin–Darby canine kidney (MDCK) cells as
described below and viral titers were calculated by the
method of Reed and Muench (28). The log10 TCID50
(50% infectious dose in tissue culture) of the virus pool
was 5.6.
Uterine infection protocol
Eight- to 10-week-old female BALB/c mice were anes-
thetized by intramuscular injection of a mixture of 1 mg
of ketamine plus 1 mg of xylazine. A 2.5-cm incision
was made parallel and dorsal to the lumbar spine, the
ovaries were exteriorized, and each ovarian bursa was in-
jected with 2  102.5 TCID50 of PR8 influenza virus (vol-
ume, 20 L), using a 30-gauge needle. The surgical pro-
cedure was performed under a dissecting microscope.
The incision was closed with 3-0 wire sutures to dis-
courage gnawing of the healing wound. At various times
postinfection, mice were killed (by intravenous injection
of 30 mg of xylazine) and the uterus was removed for
assay. The uterus and uterine horns were flushed with
600 L of cold (4°C) sterile phosphate-buffered saline
(PBS) and the wash fluid was saved for viral assay. The
washed uterus was then ground in 600 L of cold ster-
ile PBS and centrifuged at 1000 rpm to remove debris,
and the supernatants were assayed for virus. To preserve
viral viability, samples (washes and ground uterus su-
pernatants) were not frozen but were kept on ice and as-
sayed as described below within 1 h.
Viral assay
A modification of the viral assay originally developed
by Wyde et al. (47) and adapted by Bender et al. (3) was
used. Viral samples were serially diluted (10-fold) in Dul-
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becco’s modified Eagle’s medium (DMEM) supple-
mented with amphotericin B (2.5 g/mL; Sigma, St.
Louis, MO), gentamicin (50 g/mL; Sigma), and 10%
fetal calf serum (FCS). Triplicate 100-L samples of each
dilution were placed into 96-well round-bottom tissue
culture plates. To each well was added 100 L of a sus-
pension of MDCK cells (2  105 cells/mL) in supple-
mented DMEM–10% FCS. The plates were incubated for
24 h at 34°C in 5% CO2. The culture fluid was removed
and replaced with DMEM (150 L/well) containing am-
photericin B (2.5 g/mL), gentamicin (50 g/mL), and
trypsin (2 g/mL) (DMEM–trypsin). The plates were
then incubated for 4 d at 34°C in 5% CO2. Assay for vi-
ral growth was by hemagglutination (HA). To each well
was added 50 L of a 0.5% suspension of chicken red
blood cells (CRBCs). HA was read after 1–2 h in the
cold. Viral titers were calculated by the method of Reed
and Muench (28).
Histology
Uteri were removed from killed normal mice or from
mice infected intrabursally 96 h previously with influenza
virus. One horn of each uterus was processed for light
microscopy and one for scanning electron microscopy.
For light microscopy, samples were fixed in 10% neutral
buffered formalin, embedded in paraffin, cut into 2-m
sections, and stained with hematoxylin and eosin. For
electron microscopy, samples were fixed in glutaralde-
hyde–cacodylate buffer (2.5% glutaraldehyde dissolved
in 0.1 M sodium cacodylate buffer) and stored at 4°C un-
til processed. For processing, samples were postfixed
with 1% osmium tetroxide, dehydrated with successive
transfers to 70%, 90%, and absolute ethanol, and dried
in a desiccator after treatment with hexamethyldisilane.
The samples were then mounted and coated to a thick-
ness of 80 nm with gold–palladium.
Protection protocol
Female BALB/c mice were injected intravenously via
the tail vein with 200 L of H66-37-1 or Z-F11-15 as-
cites mixed with 200 L of saline. The ascites was cen-
trifuged before injection to preclude embolus formation.
Four hours later, the mice were anesthetized and infected
as previously described. In some cases, mice were in-
fected first and injected with H66-37-1, 30 min later.
Mice were killed at various times postinfection and their
uteri were assayed for viral growth as described.
Antibody transport protocol
Twelve 8- to 10-week-old female BALB/c mice were
injected intravenously via the tail vein with 200 L of
pIgA anti-influenza mAb-containing ascitic fluid that had
been centrifuged to preclude embolus formation and
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mixed with 200 L of saline (dose of 1700 g of pIgA
per mouse). At 2, 4, and 8 h postinjection four mice were
injected intravenously with 30 mg of xylazine. The chest
was opened and the mouse was perfused with PBS to
minimize contamination of uterine lavages with blood
contained within the vascular system. An 18-gauge nee-
dle attached to a 60-mL syringe containing 50 mL of PBS
was placed in the left ventricle of the heart and clamped
in place with a hemostat. An incision was made in the
right ventricle to allow drainage and the circulatory sys-
tem was perfused with the PBS. Perfusion was monitored
by observation of the liver, which became clay-colored
as blood was flushed from the system. The intact uterus
was then clamped proximal to the cervix with a curved
hemostat and excised with the cut immediately proximal
to the cervix, its exterior rinsed with PBS to remove any
trace of blood, and the interior lavaged with 600 L of
PBS, which was flushed once through each horn and col-
lected in a microcentrifuge tube as it drained from the
distal end of the uterus.
Antibody titer determination
Uterine wash pIgA anti-influenza virus mAb titers
were determined by a modification of the enzyme-linked
immunosorbent assay (ELISA) previously described
(32). PR8 influenza vaccine (the gift of F. Brandon,
Parke, Davis, and Co., Rochester, MI) was dried onto 96-
well flat-bottom enzyme immunoassay (EIA) microtiter
trays (EIA II Plus microtitration plates; MP Biomedicals,
Solon, OH). Unreacted sites were blocked overnight at
4°C with PBS–Tween containing 1% bovine serum al-
bumin (BSA) for ELISA diluent applications (Sigma) and
1% normal rabbit serum (NRS). All antibodies were di-
luted in PBS–Tween containing 1% bovine serum albu-
min (BSA) and 1% NRS and PBS–Tween was used for
all plate washes. After overnight blocking, the plates were
washed, uterine wash samples were added in triplicate,
and the trays were incubated overnight at 4°C. The plates
were washed, and the second and third antibodies were
added and incubated for 1.5 h at room temperature. Affin-
ity-purified goat anti-mouse IgA was the second anti-
body, and the final antibody was rabbit anti-goat IgG cou-
pled to alkaline phosphatase (NRS and both antibodies
were obtained from Sigma). Reaction with the substrate
p-nitrophenyl phosphate (Sigma) produced a yellow color
that was read at 405 nm as an end-point ELISA on a
Spectromax 190 ELISA reader (Molecular Devices, Sun-
nyvale, CA). Titers were calculated from sample dilu-
tions relative to a dilution of the standard pIgA mAb. The
titer is defined as the ratio of the dilution of sample re-
quired to give a specific ELISA optical density (OD) to
the dilution of the standard required to give the same OD
(parallel line method), expressed as a percentage. For ex-
ample, a sample with a titer of 1  103 contains 0.001%
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as much antibody as the ascites standard. The ascites pool
used as the standard contained an 8.6-mg/mL concentra-
tion of pIgA anti-influenza virus mAb. Standard wells
containing known concentrations of mAb from this pool
were included on each ELISA plate so that the concen-
tration of transported mAb in the uterine lavages could
be readily determined.
Because binding of antibody to the influenza vaccine-
coated plates requires antibody specificity, this ELISA
detects only the intravenously injected influenza virus-
specific mAb.
Statistics
All data are expressed as means  SD. Nonparamet-
ric (Mann–Whitney) and parametric (analysis of variance
[ANOVA] and Fisher’s protected least significant dif-
ference [PLSD]) analyses were carried out on a Macin-
tosh Performa using StatView 4.2 (SAS Institute, Cary,
NC) software.
Graphics
Figures were generated with CA-Cricket Graph III
software (CA, Islandia, NY) on an Apple iBook (Apple
Computer, Cupertino, CA). Photomicrographs were also




Influenza virus grows in the murine uterus
Growth of PR8 influenza virus in the murine uterus is
shown in Fig. 1. Similar viral titers (104 to 105 TCID50)
were reached in both uterine washes and ground uterus.
The highest virus titers occurred 3 to 5 d after infection.
This finding mimicks the growth pattern seen in the nose,
trachea, and lungs when the influenza virus is inoculated
into the noses of awake nonimmune mice (24).
Histologic studies were performed 96 h after viral in-
fection, at the time of peak viral titer. By light mi-
croscopy, the most notable pathology associated with vi-
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FIG. 1. Growth of influenza virus in the murine uterus.
Mice were infected via injection of the ovarian bursa with 2 
102.5 TCID50 of PR8 influenza virus. Mice were killed and uteri
were assayed for virus in uterine washes (solid squares) or
ground uterus (open squares) at various times after infection.
Each point represents four to six animals.
FIG. 2. Light microscopy of the murine oviduct. Mice were
infected via injection of the ovarian bursa with 2  102.5
TCID50 of PR8 influenza virus. Ninety-six hours postinfection,
infected and noninfected control animals were killed and the
uterus was removed for light and scanning electron microscopy
analysis. Normal murine oviduct is lined by ciliated cells with
tapered tips [arrow in (A)]. After influenza infection, the cilia
were lost and the epithelial cells lining the interior of the ovar-
ian bursa were necrotic with condensed, pycnotic nuclei and in-
distinct cellular outlines. Areas of desquamation [arrows in (B)]
were evident. Original magnification: 400.
lining the oviduct (Fig. 2B). Neither the uterus nor the
oviduct displayed the extensive desquamation seen in the
tracheas of influenza virus-infected mice (13,48); how-
ever, the 96-h time frame may have been too short for
the full pathologic effects of the infection to develop, The
ciliated columnar epithelial cells lining the oviduct of in-
fected mice appeared necrotic, with pycnotic nuclei and
indistinct cellular outlines. Areas of limited desquama-
tion were present and cells within the submucosa were
farther apart than those in the noninfected tissue, sug-
gesting the presence of interstitial edema. The uterine ep-
ithelium showed similar pathology, with pycnotic nuclei,
indistinct cellular architecture, and minimal desquama-
tion. Scanning electron microscopy (Fig. 3) confirmed
the clipping of the cilia of the oviduct. In normal mice,
the oviduct was characterized by both short microvilli
and longer cilia with slightly rounded tapered tips (Fig.
3A). In infected mice, both the microvilli and the cilia
were severely blunted. The cilia were shortened and de-
formed (Fig. 3B) and, in some cases, adhered to each
other (Fig. 3C).
Influenza virus-specific pIgA is transported 
into the uterus
To demonstrate that intravenously administered pIgA
can be transported into the uterus, a single intravenous
injection of 1700 g of pIgA anti-influenza virus mAb
(the dose shown to saturate the murine transport system
[30,32]) was administered to 12 mice. Four mice were
killed 2, 4, or 8 h postinjection and uterine lavages were
performed to harvest the transported antibody. Passively
administered pIgA antibody was, as previously reported
in the rat, transported into murine uterine secretions (46).
The pattern (Fig. 4A and B) resembles that seen in nasal
lavages of pIgA-injected mice (32), with peak transport
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of 2.62  3.87 g (or 0.154% of the injected dose) of
pIgA anti-influenza mAb per uterus reached by 4 h
postinjection.
Influenza virus-specific pIgA protects the uterus
from infection
H66-37-1 is a pIgA mAb directed toward the H1
hemagglutinin of the A/PR8 influenza virus. We have
shown that it can be transported into the bile of Lewis
rats, acquiring SC in the process (31), and into murine
nasal secretions, presumably also by the pIgR, and that
the transported antibody retains its polymeric form and
can prevent infection of the murine nose by influenza
virus (30,32). To determine whether this antibody can
also protect the murine uterus from viral infection, fe-
male BALB/c mice were injected intravenously with
1700 g of pIgA anti-influenza virus mAb or with saline
4 h before injection of virus into the ovarian bursa. Vi-
ral growth in passively immunized animals was deter-
mined 1, 2, and 3 d after viral infection (Table 1). On
days 1 and 2 all the mice injected with influenza virus-
specific pIgA mAb were protected from viral infection,
regardless of whether uterine washes or ground uteri were
assayed. On day 3, 9 of 12 uterine washes and 7 of 8
ground uteri from H66-injected mice showed no viral in-
fection (Table 1). Those influenza virus-specific pIgA
mAb-injected mice that shed virus (Table 2) did so at a
reduced titer relative to saline-injected mice whether in
uterine washes (p  0.001) or ground uterus (p  0.05).
Injection of Z-F11-15, a pIgA of unrelated specificity,
did not protect against influenza virus infection.
Under the standard protocol, mice were injected first
with antibody, and then challenged with virus. To rule
out the possibility that blood with a high titer of influenza
virus-specific pIgA leaking into the ovarian bursa via the
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FIG. 3. Scanning electron photomicrographs of the murine oviduct. Mice were infected via injection of the ovarian bursa
with 2  102.5 TCID50 of PR8 influenza virus. Ninety-six hours postinfection, infected and noninfected control animals were
killed and the uterus was removed for light and scanning electron microscopy analysis. Epithelial cells lining the normal murine
oviduct (A) bear both long cilia and shorter microvilli. These cilia, like those of the respiratory tract, have tapered tips. In the
influenza virus-infected oviduct, microvilli and cilia are short and blunted (B) and, in some cases, form clumps (C). Original
magnification: 10,000. Scale bars: 1 m.
small puncture at the inoculation site was neutralizing the
virus before initial cellular infection, mice were first in-
fected with influenza virus, and then injected with anti-
body 30 min later, allowing the initial stage of viral in-
fection to occur before antibody injection. Mice treated
in this manner were still protected (Table 2), suggesting
that protection was due to antibody transported into the
uterus, preventing further rounds of viral replication, and
not to antibody-containing blood leaking into the ovar-
ian bursa at the time of viral inoculation.
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DISCUSSION
Passive immunization studies of the murine respiratory
and gastrointestinal tracts have shown that S-IgA alone
is able to mediate local immunity against viruses
(18,32,41,42) and bacteria (8,45). The genitourinary tract
is an important port of entry for pathogenic viruses and
microorganisms. Involvement of S-IgA in uterine or cer-
vicovaginal immunity has been implied by a number of
studies correlating antibody levels with protection and/or
recovery from infection (1,7,14,17,21–23,25,27,29,36,
43) and by two studies in which the continuous secretion
of a high level of pIgA anti-Chlamydia mAb from a
“backpack” tumor was able to slow the progress of
chlamydial infection into the uterus after vaginal chal-
lenge in the mouse (8,26); however, there are no studies
directly demonstrating the role of S-IgA in antiviral im-
munity in the female reproductive tract, possibly because
of the complexity of the immune response to two of the
major pathogens of interest, that is, the human immuno-
deficiency virus and herpes simplex virus type 2 viruses,
and the difficulty in propagating these pathogens in the
murine model. The demonstration of this immunity re-
quires, first, a model for the consistent infection of the
uterus and, second, an agent-specific pIgA capable of
neutralizing the growth of the infective agent and of be-
ing transported to its potential site of action in vivo by
the pIgR. Herein, we have demonstrated that the in-
fluenza virus model meets these requirements.
Although influenza virus is not a normal pathogen of
the reproductive tract, the influenza viral infection model
is one of the best characterized as far as antibody selec-
tive transport, isotype involvement, viral neutralization,
and in vivo protection from viral infection are concerned.
In addition, mice are easily infected with the mouse-
adapted PR8 influenza virus, the virus is easy to propa-
gate and assay in vitro, its cellular receptors are well
known, and it is safe to handle under general laboratory
conditions
Sweet et al. (40) showed that influenza virus grew in
the oviduct of fetal ferrets. Additional studies with guinea
pigs (39) and human fetal tissue (34) further demon-
strated the growth of influenza virus in genitourinary tis-
sues. We found that PR8 influenza virus, when injected
into the ovarian bursa, was also capable of growing in
the mature murine uterus. Infection was consistent and
reproducible: virus could be detected in uterine secretions
(uterine washes) or in uterine tissue in comparable
amounts (Fig. 1). Pathologic changes associated with vi-
ral infection were most severe in the ciliated cells of the
oviducts (Figs. 2 and 3), which underwent necrosis, los-
ing their cilia in the process. Areas of desquamation were
noted, as well as interstitial edema within the oviduct.
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FIG. 4. Transport of pIgA anti-influenza virus mAb into
the murine uterus. Mice were injected intravenously with 1700
g of pIgA anti-influenza virus mAb. At various times postin-
jection, mice were killed and the total amount of mAb (A) re-
covered per uterus was determined by ELISA analysis. The per-
centage of the injected dose of pIgA anti-influenza virus mAb
recovered per uterus is shown in (B). n  4 mice per time point.
severe, pathology. The viral pathology was not dissimilar
to that seen in influenza viral infection of the murine res-
piratory tract, where the ciliated cells of the trachea undergo
complete desquamation (13,48); while the ciliated cells of
the nose show blunting of the ciliary tips (33).
Renegar and Small (32) showed that the anti-influenza
virus pIgA mAb used in this study could be selectively
transported into nasal secretions relative to monomeric
immunoglobulin, that the time of peak transport was 4 h
after injection, and that transported antibody was able to
protect the nose against influenza viral infection. In this
paper, we show that intravenously injected pIgA anti-
influenza virus mAb is also transported into uterine 
secretions and that peak transport, like that seen in the
respiratory tract, occurs 4 h postinjection. The pIgA anti-
influenza virus mAb pool contained approximately 25%
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monomeric IgA, and therefore we cannot exclude the pos-
sibility that monomeric influenza-specific IgA mAb con-
tributed to the observed uterine protection; however, be-
cause the polymeric form of pIgA comprised at least 75%
of the pIgA pool used for injection and because any
monomeric IgA included in the mAb dose would have
been diluted in the normal intravascular monomeric im-
munoglobulin pool, we believe that protection in our
model was due to S-IgA transported into the uterus by
the pIgR. Sullivan and Wira (38) reported that uterine tis-
sues were saturated with pIgA antibody by 2 to 4 h postin-
jection and that pIgR-mediated transport was seen by 4
h postinjection in estrogen-treated ovariectomized female
rats. This is consistent with the 4-h postinjection IgA peak
we observed. We have shown (30,32) that in mice the
percent injected dose of monomeric immunoglobulin
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TABLE 1. EFFECT OF PRETREATMENT WITH INTRAVENOUS pIgA ANTI-INFLUENZA VIRUS mAb ON INTRAUTERINE
VIRAL MULTIPLICATION IN MICE INFECTED VIA THE OVARIAN BURSA WITH INFLUENZA VIRUS
Uterine washes Ground uterus
Mouse treatment Mouse treatment
Intravenous saline Intravenous pigA Intravenous saline Intravenous pigA
(no. mice (no. mice (no. mice (no. mice
Day shedding virus/ shedding virus/ shedding virus/ shedding virus/
post total no. infected total no. infected total no. infected total no. infected
infection mice) mice) mice) mice)
1 3/3 0/2 (p  0.05)a 3/3 0/2 (p  0.05)
2 5/6 0/6 (p  0.01) 6/6 0/6 (p  0.01)
3 6/6 3/12 (p  0.01) 6/6 1/8 (p  0.002)
aMann-Whitney nonparametric analysis, saline versus pIgA.
TABLE 2. EFFECT OF PRE- OR POSTVIRAL CHALLENGE WITH INTRAVENOUS pIgA ANTI-INFLUENZA
VIRUS mAb ON 72-h POSTINFECTION VIRAL TITERS IN MICE INFECTED WITH INFLUENZA VIRUS
VIA THE OVARIAN BURSAa
Uterine washes Ground uterus
Log10 titer No. mice shedding Log10 titer No. mice shedding
Mouse virus in virus/total no. virus in virus/total no.
treatment washes mice infected tissue mice infected
A. Intravenous saline ➔ virus 4.77  5.2 8/8 5.95  6.4 7/7
B. H66 pIgA ➔ virus 0.15  0.28 1/8 0.57  0.12 1/8
C. ZF11 pIgA ➔ virus 4b 5/5 4b 5/5
D. Virus ➔ H66 pIgA 0 0/2 0 0/2
aParametric statistical analysis (ANOVA and Fisher’s PLSD post hoc): Uterine washes: A vs. B, p  0.001; B vs . C, p  0.0001;
A vs. D, p  0.02; one mouse in group A with excessively high viral titers was excluded from statistical calculations. Ground
uterus: A vs. B, p  0.05; B vs. C, p  0.0001; C vs. D, p  0.0001; one mouse in group A with excessively high viral titers was
excluded from statistical calculations. Nonparametric statistical analysis (Mann–Whitney): Uterine washes: A vs. B, p  0.005; A
vs. D, p  0.04; B vs. C, p  0.02. Ground uterus: A vs. B, p  0.005; A vs. D, p  0.05; B vs. C, p  0.02.
bTiters of all mice were in excess of 3.5
reaching the secretions remains relatively constant with
increasing time postinjection, whereas the percent in-
jected dose of pIgA peaks and then drops as hepatobil-
iary pIgR rapidly removes polymeric immunoglobulins
from the circulation. In our uterine transport model (Fig.
4A and B), both the uterine anti-influenza virus mAb titer
and the percent injected dose peaked 4 h postinjection.
After this peak, both transport parameters fell to the 2-h
level. This pattern is consistent with transport of pIgA
into the uterus by the pIgR. Furthermore, selective trans-
port into the murine uterus of pIgA relative to monomeric
immunoglobulin has been shown to occur (selective
transport index 4 h after antibody injection, 6.2  5.2;
K.B. Renegar, unpublished data), indicating that pIgR-
mediated uterine transport of pIgA takes place. Hence,
we believe that S-IgA mediated the uterine immunity in
our model.
We investigated uterine immunity using the same
virus–antibody system previously used to study nasal im-
munity. As with protection of the respiratory tract, a sin-
gle dose of anti-influenza virus pIgA mAb administered
4 h before viral challenge was able to protect the murine
oviducts and uterus from influenza virus infection (Ta-
bles 1 and 2). Protection required specific antibody and
occurred regardless of the order in which antibody and
virus were administered. Because monomeric im-
munoglobulins readily enter uterine secretions, it is likely
that not only pIgR-transported pIgA but also plasma in-
fluenza virus-specific IgG mAb can confer protection on
the uterus. Further studies are required to delineate more
completely the roles of IgA and IgG in uterine immunity.
In conclusion, we have shown that influenza virus will
grow in the murine uterus, providing a model for the
study of uterine immunity. Intravenously injected in-
fluenza virus-specific pIgA mAb was transported into the
uterus and protected the uterus against viral infection.
This is the first direct demonstration of the prevention of
uterine viral infection by pIgA and we believe that it is
also the first direct demonstration of the mediation of an-
tiviral immunity in the uterus by S-IgA. This model
should be useful in delineating the relative roles of IgA
and IgG in uterine immunity; moreover, it should prove
a valuable tool in determining the effect of hormonal vari-
ation on antibody-mediated uterine immunity.
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